Skip to main content

Advertisement

SpringerLink
Log in

Soluble CD21 in sera and synovial fluid of arthritic patients

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Soluble CD21 (sCD21) is the ectodomain of the CD21 glycoprotein released by shedding from the cellular membrane. The ectodomain of CD21 is capable of binding complement fragments, Epstein-Barr virus (EBV) and CD23. Functionally sCD21 can activate monocytes and abrogate B-cell/follicular dendritic cell interaction, thereby inhibiting antibody production by antigen primed B cells. Levels of sCD21 vary in several clinical conditions. Here we analyzed sCD21 in synovial fluids and sera in arthritic patients. sCD21 concentrations were consistently lower in synovial fluids compared to paired sera samples from the same patients. In contrast to healthy donors, sCD21 levels are significantly reduced in rheumatoid arthritis patient’s sera. Potential causes and consequences of the data are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Corr M, Firestein GS (2002) Innate immunity as a hired gun: but is it rheumatoid arthritis? J Exp Med 195:F33–F35

    Article  CAS  PubMed  Google Scholar 

  2. Feldmann M, Brennan FM, Maini RN (1996) Rheumatoid arthritis. Cell 85:307–310

    Article  CAS  PubMed  Google Scholar 

  3. Harris EDJ (1997) Rheumatoid arthritis, 1 edn. W.B.Saunders, California

    Google Scholar 

  4. Mollnes TE, Lea T, Mellbye OJ, Pahle J, Grand O, Harboe M (1986) Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum 29:715–721

    CAS  PubMed  Google Scholar 

  5. Heaney ML, Golde DW (1998) Soluble receptors in human disease. J Leukoc Biol 64:135–146

    CAS  PubMed  Google Scholar 

  6. Dello SP, Rovida E (2002) Transmodulation of cell surface regulatory molecules via ectodomain shedding. Biol Chem 383:69–83

    Article  PubMed  Google Scholar 

  7. Fearon DT, Carroll MC (2000) Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 18:393–422

    Article  CAS  PubMed  Google Scholar 

  8. Ling NR, Brown B (1992) Properties of soluble CR2 in human serum. Immunobiology 185:403–414

    CAS  PubMed  Google Scholar 

  9. Huemer HP, Larcher C, Prodinger WM, Petzer AL, Mitterer M, Falser N (1993) Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol 93:195–199

    CAS  PubMed  Google Scholar 

  10. Fremeaux-Bacchi V, Aubry JP, Bonnefoy JY, Kazatchkine MD, Kolb JP, Fischer EM (1998) Soluble CD21 induces activation and differentiation of human monocytes through binding to membrane CD23. Eur J Immunol 28:4268–4274

    Google Scholar 

  11. Qin D, Wu J, Carroll MC, Burton GF, Szakal AK, Tew JG (1998) Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 161:4549–4554

    Google Scholar 

  12. Fremeaux-Bacchi V, Kolb JP, Rakotobe S, Kazatchkine MD, Fischer EM (1999) Functional properties of soluble CD21. Immunopharmacology 42:31–37

    Google Scholar 

  13. Illges H, Braun M, Peter HH, Melchers I (2000) Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clin Exp Immunol 122:270–276

    Article  CAS  PubMed  Google Scholar 

  14. Masilamani M, Seydlitz EV, Bastmeyer M, Illges H (2002) T cell activation induced by cross-linking CD3 and CD28 receptors leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Immunobiology 206:528–536

    CAS  PubMed  Google Scholar 

  15. Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H (2004) Reduction of Soluble Complement Receptor II/CD21 in Systemic Lupus Erythomatosus and Sjoegren’s Syndrome but not Juvenile Arthritis. Scand J Immunol (in press)

  16. Masilamani M, von Kempis J, Illges H (2004) Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology (Oxford) 43:186–190

    CAS  Google Scholar 

  17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    CAS  PubMed  Google Scholar 

  18. Cronstein BN, Eberle MA, Gruber HE, Levin RI (1991) Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 88:2441–2445

    Google Scholar 

  19. Gu B, Bendall LJ, Wiley JS (1998) Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 92:946–951

    CAS  PubMed  Google Scholar 

  20. Papiha SS, Pal B, Walker D, Mangion P, Hossain MA (1989) Alpha 1 antitrypsin (PI) phenotypes in two rheumatic diseases: a reappraisal of the association of PI subtypes in rheumatoid arthritis. Ann Rheum Dis 48:48–52

    CAS  PubMed  Google Scholar 

  21. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Levarht EW, Breedveld FC, Verweij CL (1998) Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum 41:2211–2220

    Google Scholar 

  22. Masilamani M, Kassahn D, Mikkat S, Glocker MO, Illges H (2003) B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol 33:2391–2397

    Google Scholar 

Download references

Acknowledgements

This work was supported by the Hans-Hench-Stiftung, the Thurgauische Stiftung für Wissenschaft und Forschung through the Kanton Thurgau and the Bundesamt für Bildung und Wissenschaft (BBW), Bern, Switzerland through grant QLG1-CT-2001-01536 to HI.

Author information

Authors and Affiliations

  1. Biotechnology Institute Thurgau, Konstanzerstr. 19, 8274, Tägerwilen, Switzerland

    Thomas Grottenthaler & Harald Illges

  2. Division of Rheumatology and Clinical Immunology, Kantonsspital St.Gallen, 9007, St.Gallen, Switzerland

    Johannes von Kempis

  3. Division of Rheumatology and Clinical Immunology, University of Freiburg Medical Center, Hugstetterstr. 55, 79106, Freiburg, Germany

    Sigune Goldacker

  4. Department of Natural Sciences, University of Applied Sciences, 53359, Rheinbach, Germany

    Harald Illges

Authors
  1. Thomas Grottenthaler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes von Kempis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sigune Goldacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harald Illges
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harald Illges.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grottenthaler, T., Kempis, J.v., Goldacker, S. et al. Soluble CD21 in sera and synovial fluid of arthritic patients. Rheumatol Int 26, 240–243 (2006). https://doi.org/10.1007/s00296-004-0541-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-004-0541-2

Keywords

Search

Navigation